The novel coronavirus (nCoV-2019) outbreak in Wuhan, China has spread rapidly nationwide, with some cases occurring in other parts of the world. Although most patients present with mild febrile illness with patchy pulmonary inflammation, a significant portion develop severe acute respiratory distress syndrome (ARDS), with a current case fatality of 2.3-3%. Diagnosis is based on clinical history and laboratory and chest radiographic findings, but confirmation currently relies on nucleic acid-based assays. The latter are playing an important role in facilitating patient isolation, treatment and assessment of infectious activities. However, due to their limited capacity to handle an epidemic of the current scale and insufficient supply of assay kits, only a portion of suspected cases can be tested, leading to incompleteness and inaccuracy in updating new cases, as well as delayed diagnosis. Furthermore, there has not been enough time to assess specificity and sensitivity. Conventional serological assays, such as enzyme-linked immunoassay (ELISA) for specific IgM and IgG antibodies, should offer a high-
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throughput alternative, which allows for uniform tests for all suspected patients, and can facilitate more complete identification of infected cases and avoidance of unnecessary cross infection among unselected patients.
Keywords: nCoV-2019; coronavirus; serologic assay; diagnosis; pneumonia, antibody In December 2019, an acute febrile illness with severe respiratory distress syndrome (ARDS) started to occur in Wuhan, Hubei Province, China 1-3 . Most patients developed patchy to diffuse infiltration of the lungs radiographically 2 [Figure 1 ]. It was found that most early cases were linked to a local fresh seafood market, the Huanan Seafood Market, although some-particularly later cases-were not 2 . Initial investigations identified a novel bat coronavirus as a possible culprit, which was subsequently confirmed by detection of viral sequences by multiple teams independently, and by virus isolation from the lower respiratory tracts of patients 3, 4, 7 . The novel virus has been named novel coronavirus (nCoV)-2019. Genomic sequences of viruses from 5 cases are shown to be almost identical to one another, with homology of 79.5% to SARS-CoV and 85-96% to a bat SARS-like coronavirus (bat-SL-CoVZC45) at the whole genome level 4 . The outbreak thus represents a new emerging viral disease due to species jumping of a virus to humans.
Initially, it was thought that the infection showed no or limited human-to-human transmission. However, soon after it became evident that transmission among humans constitutes main mechanism of infection spread, in community, healthcare facilities, and at home. The diagnoses were made purely based on clinical and radiographical grounds, lack of response to antibiotic therapy, and exclusion of other common respiratory infections for the season 1-3 . With the newly identified genetic sequence information, diagnostic tests based on detection of the viral sequence by reverse-transcriptase polymerase chain reaction (RT-PCR) or next generation sequencing platforms soon became available. This allowed for diagnosis confirmation and better estimates of infection activity, which was found to be increasing in alarming speeds. The municipal government issued a public warning and implemented a total shutdown of transportation on January 23, 2020, advising individual isolation. On January 30, 2020, a World Health The common (mild) cases are those with fever, respiratory symptoms, and pneumonia on chest radiography. Severe cases need to meet one of the following criteria:
(1) respiratory distress, RR>=30/min; (2) resting blood oxygen saturation =< 93%; or (3) arterial blood oxygen partial pressure (PaO2)/FiO2 =<300 mmHg. Critical cases meet one of the following: (1) respiratory failure needing mechanical oxygenation; (2) shock; or (3) development of other organ failure, requiring intensive care unit (ICU) care.
Around 70-80% of patients are mild, and 20-30% are severe or critical (Peng ZY, personal communication).
The diagnosis needs to be differentiated from influenza, parainfluenza, adenovirus, respiratory syncytial virus (RSV), rhinovirus, SARS coronavirus, mycoplasma, chlamydia and bacterial pneumonia, as well as non-infectious diseases such as vasculitis 2, 8 .

Diagnosis using the RNA-based assays
Currently, diagnosis of suspected cases is confirmed by RNA tests with real-time RT-PCR or next-generation (NextGen) sequencing. It had been shown that viral RNA can be detected from nasal and pharyngeal swab, bronchoalveolar lavage (BAL), and blood plasma using RT-PCR targeting the NP gene of the virus 2, 4, 8 . Prior to the Wuhan city-wide shutdown, specimens for confirmatory tests had to be sent to China CDC (CCDC), with a long turn-around time. Subsequently, several main tertiary care hospitals in Wuhan were authorized to perform the tests. Therefore, in the earlier stages of the outbreak, a very limited number of patients were tested and confirmed for the diagnosis.
Since January 25, tests have become increasingly available for clinically suspected patients, with a history of exposure, fever, and positive findings on chest CT. However, since only a limited number of tests can be offered each day due to limited supplies and lab facilities, only a portion of the targeted population received tests. For example, during the month of January 2020, only 1,700 specimens were tested (media report by the hospital on WeChat, 1/29/2020), compared to the vast number of clinic patients during that period (between January 22 and 30 alone, there were over 7,000 visits to one of the designated fever clinic). This created a significant backlog, as many patients had to wait for days to receive a confirmation or exclusion of diagnosis. It also led to problems in real-time reporting, causing artificial fluctuation in daily updates of new cases ( Figure   2B ). For example, as shown in Table 1 Another concern related to the nucleic acid tests is that there has not been sufficient time to assess their sensitivity and specificity. Based on personal communications with colleagues, a significant portion of patients who otherwise fit the diagnosis based on clinical and chest CT findings, including many hospitalized patients, have tested negative for viral RNA. Other common respiratory etiologies, such as influenza, were excluded. These remain "suspected" cases and may be reflective of false This article is protected by copyright. All rights reserved.
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negativity in sampling. In some patients, the virus may be present in the lower respiratory secretion but absent in the upper respiratory tracts.
With the current tests, it is therefore difficult to achieve a meaningful assessment of what proportion of symptomatic patients are infected. As we know, production of host antibodies to a specific virus during an acute phase infection is consistent in most patients, except for those with immunodeficiency.
Serological assays are needed
The IgM antibody can be detected as early as day 3 in many infections. The requirement for specimen quality is less stringent than for RNA-based assays. Whether viruses themselves are present in respiratory specimens, the presence of a specific antibody can be uniformly detected, avoiding false negative results due to sampling. Most importantly, with the regular 96-well microplate, and automatic ELISA devices, the test capacity is greatly increased compared to RNA-based molecular tests and can handle a large number of febrile patients such as in the current epidemic, with a quick turnaround time (2-3 hours). For example, hemorrhagic fever with renal syndrome caused by hantavirus was endemic in Hubei Province, with high annual incidence in the 1980s and 1990s. Rapid 
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Serologic tests can be easily implemented in the clinical laboratory of any hospital, thus with a much wider application than molecular tests.
Another issue for consideration is reporting of asymptomatically infected cases, or very mild cases of infection who are a large group of patients but not tested for viral RNA (which is impractical), therefore making the true rate of infection in the population unknown. With development of a specific IgG antibody test, a large-scale seroepidemiological study can be conducted after the end of the current outbreak, so that we can understand the true scale of human-to-human transmission of the novel coronavirus of 2019.
A fast-performing serologic assay is acutely needed for the current and future outbreaks.
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The author has no conflicts of interest to disclose. she had dry cough, chest tightness, and shortness of breath for a week. Her body temperature at presentation was 38.8 C. CBC showed WBC 4.6*10^9/L, neutrophilic differential 65.8%, and lymphocytic differential 19.9% (reduced).
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